Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2017

Routine pre-treatment MRI for breast cancer in a single-payer
medical center: Effects on surgical choices, timing and outcomes
Timothy J. Vreeland
Womack Army Medical Center

John S. Berry IV
Washington University School of Medicine in St. Louis

Erika Schneble
San Antonio Military Medical Center

Doreen O. Jackson
San Antonio Military Medical Center

Garth S. Herbert
San Antonio Military Medical Center

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Vreeland, Timothy J.; Berry IV, John S.; Schneble, Erika; Jackson, Doreen O.; Herbert, Garth S.; Hale, Diane
F.; Martin, Jonathon M.; Flores, Madeline; Pattyn, Adam R.; Hata, Kai; Clifton, Guy T.; Kirkpatrick, Aaron D.;
and Peoples, George E., ,"Routine pre-treatment MRI for breast cancer in a single-payer medical center:
Effects on surgical choices, timing and outcomes." Journal of Cancer. 8,13. . (2017).
https://digitalcommons.wustl.edu/open_access_pubs/6138

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Authors
Timothy J. Vreeland, John S. Berry IV, Erika Schneble, Doreen O. Jackson, Garth S. Herbert, Diane F. Hale,
Jonathon M. Martin, Madeline Flores, Adam R. Pattyn, Kai Hata, Guy T. Clifton, Aaron D. Kirkpatrick, and
George E. Peoples

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/
open_access_pubs/6138

Journal of Cancer 2017, Vol. 8

Ivyspring

International Publisher

Research Paper

2442

Journal of Cancer

2017; 8(13): 2442-2448. doi: 10.7150/jca.16738

Routine Pre-Treatment MRI for Breast Cancer in a
Single-Payer Medical Center: Effects on Surgical
Choices, Timing and Outcomes
Timothy J Vreeland1, John S Berry IV2, Erika Schneble3, Doreen O Jackson3, Garth S Herbert3, Diane F
Hale3, Jonathon M Martin3, Madeline Flores3, Adam R Pattyn4, Kai Hata3, Guy T Clifton3, Aaron D
Kirkpatrick5, George E. Peoples6
1.
2.
3.
4.
5.
6.

Womack Army Medical Center. Department of Surgery. Fort Bragg, NC USA;
Washington University School of Medicine. Department of Surgery. St. Louis, MO USA;
San Antonio Military Medical Center. Department of Surgery. Ft Sam Houston, TX USA;
Madigan Army Medical Center. Department of Surgery. Ft Lewis, WA USA;
San Antonio Military Medical Center. Department of Radiology. Ft Sam Houston, TX USA;
Cancer Vaccine Development Program. San Antonio, TX USA.

 Corresponding author: Timothy J Vreeland, MD, 2817 Reilly Rd, Fort Bragg, NC 28307 Cell phone: 6363465458 email: vreelant@gmail.com
© Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license
(https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Received: 2016.07.05; Accepted: 2017.03.08; Published: 2017.07.23

Abstract
Introduction: Pre-operative MRI is being used with increasing frequency to evaluate breast cancer patients,
but the debate surrounding risks and benefits of this use continues. At our institution, we instituted a
standardized protocol for pre-operative MRI. Here, we compare patients seen prior to routine use of MRI to
those seen after and examine effects on surgical choices, timing and outcomes.
Methods: This is a retrospective review of a prospectively collected database of all new invasive breast
cancers seen from January 2007 to December 2012. The control group (CG) did not receive MRI, while the
MRI group (MRG) underwent MRI according to our pretreatment protocol. Groups were compared with
regards to basic demographics, initial surgical choices, need for re-excision, and surgical timing. The electronic
medical records of patients in the MRG who underwent mastectomy as their initial surgery were examined
closely to determine the main factors leading to their choice of surgery. Finally, correlation between findings
on MRI and final surgical pathology was analyzed.
Results: Of 282 patients included, 38 were in the CG and 244 in the MRG; the groups were well matched.
The MRG had a significantly higher percentage of patients choosing initial mastectomy (MRG: 47.1% vs CG
21.1%, p=0.003). Patients seen in the first 2 years of the study were less likely to choose mastectomy than
those enrolled in the latter years (29.2%vs 48.6%, p=0.004). The MRG had a lower chance of return to the
operating room for re-excision (15.2% vs 28.9%, p=0.035). The average time from initial imaging to initial
surgery was approximately the same between groups (MRG: 39.7 days vs CG 42.1 days, p=0.45) and the MRG
actually had shorter time to definitive (margin-negative) surgical management (MRG: 43.5 days vs CG: 50.3
days, p=0.079). One hundred-fifteen patients in the MRG underwent mastectomy as initial surgery. Of these,
64 (55.7%) had no additional findings on MRI and chose mastectomy based on patient preference; 30 patients
(26.1%) (29 unilateral, 1 bilateral) had mastectomy because of MRI findings. Of the 31 breasts removed (29
unilateral and 1 bilateral mastectomies) because of MRI findings, 26 (83.9%) had histologic findings that
correlated with the MRI findings, while 5 (16.1%) did not.
Conclusion: Patients receiving routine pre-treatment MRI had an increased mastectomy rate, but had a
lower re-excision rate. We found no delay to initial surgical therapy and, perhaps more importantly, a slight
decrease in time to margin-negative surgical therapy in the MRI group. Women choosing mastectomy after
MRI did so because of personal preference over half of the time, while MRI findings influenced this choice in
26% of these women. When MRI findings did lead to mastectomy, these findings were confirmed by pathology
results in the vast majority of cases.
Key words: Pre-Treatment Breast MRI, Breast Conserving therapy, Mastectomy, Re-excision Rate.
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Introduction
Over the past two decades, contrast enhanced
MRI has been integrated into the clinical evaluation of
breast cancer patients, and its use has increased
significantly across the United States (1) and Canada
(2). MRI is accepted as a screening tool in women who
are at high risk of developing breast cancer based on
increased sensitivity over mammography. Multiple
professional societies (NCCN, ACS, ACR) now
recommend screening MRI for women with a known
genetic risk factor (BRCA, Cowden Syndrome, etc),
certain environmental risk factors (radiation to chest
between age 10 and 30), or an estimated lifetime risk
of breast cancer of 20% (3-5). The indications for
pre-treatment MRI in patients carrying a diagnosis of
breast cancer, however, are much less clear. Current
NCCN
guidelines
include
a
category
2B
recommendation stating that MRI “may be used” for
staging prior to operative intervention(6), while the
American College of Radiology grades the use of MRI
in intial workup of breast cancer as a 5 on a scale from
1 to 9, classifying its use as “may be appropriate.” (4)
The lack of a clear consensus in the current literature
on this issue contributes directly to the ambiguity of
these recommendations.
The promise of MRI in the pre-treatment setting
is the same as when used for screening, namely
increased sensitivity. MRI sensitivity in detecting
multicentric (MC) and contralateral disease has been
quoted as high as 93% and 88% compared to 46% and
19%, respectively, for conventional mammogram and
ultrasound (7). This increased sensitivity seems to be
particularly valid in patients with dense breasts (8) or
with lobular cancers (9). In theory, this increase in
sensitivity should lead to fewer positive margins,
decreased re-excision rates, and potentially lower
local recurrence rates if additional clinically relevant
disease can be detected. The results of studies
examining these issues, however, have been mixed.
While increased sensitivity can be a strength, it
can also be a detriment if not coupled with
appropriate specificity. MRI has been associated with
delays in treatment, increased costs (in part due to
workup of additional findings), and increased
mastectomy rates. These delays and additional
mastectomies may be justified if the MRI findings are
confirmed by pathology findings and serve to reduce
margin positivity, but this is not always the case.
Bleicher et al. summarized these concerns well in their
report. Compared to those without MRI, patients
undergoing pretreatment MRI had a 22.4-day delay in
pretreatment evaluation and an odds ratio for
mastectomy of 1.80; simultaneously, there was no

decrease in positive margins at lumpectomy, nor a
decrease in conversion from breast conservation to
mastectomy (10). Along the same lines, Aranout, et al.
recently published a report of a population-based
study of patients in Canada over a 10-year period in
which they found that pre-treatment MRI was
associated with increased post-diagnosis imaging and
biopsies,
more
contralateral
prophylactic
mastectomies, and a greater than 30-day wait to
surgery (2).
These two reports are representative of the
literature available on this topic, with mainly
retrospective studies that involve populations where
MRI was used selectively and infrequently (only
14.8% of patients across the Aranout study had
pre-treatment MRI), opening interpretation of any
data on the subject to significant bias. Also, the
inconsistent, non-standardized use of MRI fails to
streamline the process, and could even adversely
affect the diagnostic accuracy of MRI if interpretation
is left to providers who are unfamiliar with its use. At
our institution, we have unique advantages for
evaluating routine use of pretreatment MRI. First,
patients receive care as military beneficiaries, and
pre-operative tests are performed without any need
for insurance approval. Second, patients receive all of
their cancer care in one facility, potentially
streamlining their diagnostic work-up and transitions
between providers. Finally, we instituted a diagnostic
protocol in which all patients with biopsy-proven
invasive breast cancer are scheduled for bilateral
breast MRI upon pathologic diagnosis. Our
single-payer, single institution system gives us a
distinctive opportunity to study how efficiently a
system can accomplish routine breast MRI and to
examine the effects of this test on surgical outcomes.
Barchie et al. reported our early experience with this
protocol and showed that we had no delay in therapy.
Furthermore, while mastectomies were increased,
they found high MRI sensitivity and specificity for
multifocal (MF)/MC disease (89.5% and 84.2%,
respectively) (11). In this study, we examine our
complete experience with standardized use of
pre-treatment MRI over a 6-year period.

Methods
Patient Selection
This is a retrospective review of a prospectively
collected database of all new invasive breast cancer
cases seen at San Antonio Military Medical Center
(SAMMC) from January 2007 to December 2012. We
prospectively gathered demographic, diagnostic,
http://www.jcancer.org
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pathologic and treatment information for all patients
seen in our Breast Cancer Comprehensive Care
Conference (BC4) clinic during this time. In
September 2007, we instituted a protocol of
standardized preoperative bilateral breast MRI for all
biopsy-proven invasive cancers. The protocol was
approved and monitored by the SAMMC Institutional
Review Board. Patients who did not receive MRI,
most of whom were evaluated from January 2007 to
September of 2007, constituted a control group (CG),
while patients seen after this date who received MRI
were considered the MRI group (MRG). The SAMMC
IRB waived the requirement for informed consent
prior to MRI. Patients were excluded if they were
treated with neo-adjuvant therapy, refused surgery,
had metastatic disease, had incomplete data, or were
lost to follow-up (Figure 1, consort diagram).

Treatment Protocol
The
pretreatment
MRI
protocol
was
administered exclusively at SAMMC to Tricare
beneficiaries. All patients with mammographic
abnormalities underwent image-guided biopsy.
Patients with biopsy proven invasive carcinoma were
placed into the institutionally supported imaging
pathway. A renal function panel was obtained and the
patient was scheduled for MRI at their earliest
convenience. On occasion, patients with BIRADS 5
lesions underwent MRI prior to biopsy at the
discretion of the attending radiologist. The patient
then underwent MRI, with the goal of finalized
interpretation prior to the patient’s appointment in
the multi-disciplinary BC4 clinic. Here, each patient
was seen by a surgeon, a radiation oncologist and a
medical oncologist. Providers then met, generally that
same afternoon, in a multi-disciplinary conference,
which
included
providers
from
General
Surgery/Surgical Oncology, Radiation Oncology,
Diagnostic Radiology, Medical Oncology, Pathology,
as well as a Breast Care Nurse.
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MRI Technique
MRI was conducted with 1.5 Tesla Marconi and
Siemens Esprit magnets with InVivo dedicated seven
channel breast coils. Core sequences include axial
STIR, 3D axial T1, T2 sagittal fat saturated, pre and
post dynamic contrast axial T1 SPGR fat saturated
images with and without subtraction. Post-contrast
images were repeated to 5min with 60 sec temporal
resolution. Slice thickness was 0.9mm with 0.89mm
in-plane resolution. Matrix size was 381 x 448 with
field of view of 34 x 30 cm. Coronal and sagittal
reformats were obtained. All studies were performed
at SAMMC and interpreted by board certified staff
radiologists. The MRI was scheduled at the earliest
possible time, regardless of menstrual cycle, to avoid
delay of definitive management, accepting possible
negative impact on sensitivity and specificity (12).
Contrast administration was automated with a
0.1mmol/kg gadolinium injection followed by a 10mL
flush.

Data Collection and Analysis
The breast cancer database was reviewed for
basic demographic data, histological diagnosis,
surgical interventions, and temporal relationships
between imaging, biopsy and surgery dates. Clinical
stage was determined by initial surgical specimen.
Time from initial radiologic detection to final
(margin-negative) surgical management was recorded
in order to analyze any delay in surgical treatment.
The records of patients undergoing mastectomy after
MRI were reviewed very closely to determine the
reason for their choice of mastectomy. Pre-operative
clinic notes were examined for the discussion between
patient and surgeon/oncologist and, when possible, a
reason for mastectomy was assigned based on these
notes. Final pathology reports from these cases were
also closely examined for correlation with imaging
findings.

Figure 1. Consort Diagram
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Fisher’s exact test was used to investigate if
proportional differences existed between the MRG
and the CG with regards to histological subtype,
stage, mastectomy rate, re-excision rate, and rate of
conversion from BCT to mastectomy. The Student t
test was used for statistical analysis of continuous
variables. Mann-Whitney U test was used for
comparison of independent, nonparametric variables,
including age, tumor size, and time from diagnosis to
surgery.

Results
Patients

Table 2. MRG Demographics

A total of 370 patients with invasive breast
cancer were seen in BC4 clinic between January 2007
and December 2012. Of those patients, 88 patients
were excluded: 48 underwent neoadjuant therapy, 25
were lost to follow-up, 10 had incomplete data
available, 4 had metastatic disease and 1 refused
surgery (Figure 1). Of the remaining 282 patients, 38
(13.5%) did not receive a pre-treatment MRI, most
being seen immediately prior to institution of the MRI
protocol, and made up the control group (CG). The
other 244 patients (86.5%) received pre-treatment MRI
per protocol and, thus, were the MRI group (MRG).
The MRG and CG were very well matched with
respect to age, tumor size, histology, tumor grade,
nodal status, ER positivity, HER2 positivity, and triple
negative disease (p>0.05) (Table 1).
Table 1. Demographics
Age
Size (cm)
Ductal Histology
High Grade
Node Pos
ERHER2+
Triple Neg

compared to those seen in 2009 and afterwards,
thought this difference lost significance (36.6% vs
49.3%, p=0.14).
Within the MRG, mastectomy patients had more
advanced and high-risk disease than those choosing
BCT. While MRG mastectomy and BCT patients were
similar in age, grade, ER status, and percentage with
triple negative disease, MRG mastectomy patients
had significantly larger tumors (p<0.01), more HER2+
disease (p=0.01), and more node positive disease
(p=0.05) (Table 2).

Age
Size
Ductal Histology
High Grade
Node Pos
ERHER2+
Triple Neg

BCT
59.6
1.44
90.2%
17.9%
24.4%
13.0%
7.5%
9.1%

Mastectomy
57.7
2.15
79.5%
22.2%
35.9%
16.2%
18.4%
9.6%

p value
0.20
<0.01
0.02
0.40
0.05
0.48
0.01
0.88

Re-excision Rate
Though there was a clear increase in mastectomy
as initial surgical choice within the MRG, this group
also had a lower chance of return to the operating
room for re-excision (15.2% vs 28.9%, p=0.035).
Limiting analysis to patients who initially chose BCT,
the MRG still had a lower rate of re-excision, though
not significantly (28.7 vs 36.7%, p=0.39).

Surgical Timing
MRI
58.60
1.79
85.0%
20.0%
30.0%
14.6%
12.8%
9.4%

CG
59.10
1.56
86.5%
16.2%
28.6%
18.2%
3.0%
15.2%

p value
0.78
0.34
0.81
0.59
0.86
0.59
0.10
0.30

Initial Surgical Procedure
Overall, 159 (56.4%) patients chose BCT, while
123 (43.6%) patients chose mastectomy as initial
procedure. The MRG had a significantly higher
percentage of patients choosing mastectomy as their
initial procedure compared to the CG (47.1% vs 21.1%,
p=0.003). The rate of mastectomy as initial procedure
changed over time. Regardless of group, patients seen
in the first 2 years of the study (2007-2008, n=72) were
less likely to choose mastectomy than those enrolled
in the latter years (2009-2012, n=209) (29.2%vs 48.6%,
p=0.004). Limiting analysis to the MRG, patients prior
to 2009 were also less likely to choose mastectomy

We examined the average time for each group to
get from initial imaging with suspicious findings to
surgical management. From imaging to initial
surgery, the two groups averaged roughly the same
interval (MRG: 39.7 days vs CG 42.1 days, p=0.45). We
next examined surgical timing of the two groups in
reference to a potentially more meaningful time point,
time
from
initial
imaging
to
definitive
(margin-negative) surgical management. The MRG
actually reached this endpoint on average one week
faster than the CG, with a trend toward statistical
significance (MRG: 43.5 days vs CG: 50.3 days,
p=0.079).

MRI Patients Choosing Mastectomy
There were 115 patients in the MRG who
underwent mastectomy as initial surgery; these
patients were closely reviewed to determine the
reason for mastectomy. The results of this analysis are
demonstrated in Figure 2. The reason for mastectomy
could not be clearly determined in 3 (2.6%) patients.
Seventeen (14.8%) patients had a contraindication to
http://www.jcancer.org
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Figure 2. MRG Patients chosing mastectomy

BCT prior to MRI (12 with MC disease on
mammogram or ultrasound, 4 with a history of prior
radiation, and 1 with inflammatory breast cancer), so
their decision was not affected by MRI results. One
patient was found to be BRCA positive prior to
surgery and elected to undergo bilateral mastectomy
as a result. Thirty patients (26.1%) had mastectomy
because of an MRI finding (1 patient with tumor
>5cm, 1 with chest wall involvement, 4 with MF
disease and 24 with MC disease). Sixty-four (55.7%)
patients had no additional findings on MRI and
instead had mastectomy based on patient preference.

Bilateral Mastectomy
A total of twelve patients in the MRG had
bilateral mastectomies, 2 because of imaging findings
and 10 for prophylaxis. Of the 2 patients with imaging
findings, 1 patient had findings of bilateral disease on
mammogram (MRI did showed a corresponding
finding), with corresponding pathology results. The
other patient had no mammographic evidence of
disease on the contralateral side, but MRI showed an
area of suspicion, which was recommended for
biopsy. This patient chose to forego second biopsy
and instead to have bilateral mastectomies. Final
pathology from the contralateral breast did show
DCIS in the area that was suspicious on MRI. In the
remaining 10 patients, contralateral MRI was negative
and pathology showed no areas of DCIS or invasive
malignancy. Overall, MRI correctly identified two
cases of contralateral disease, one of which was not
seen on other imaging modalities.

MRI/Pathology Correlation
Of the 31 breasts removed from 30 patients (29
unilateral, 1 bilateral mastectomies) because of new
MRI findings, 26 (83.9%) had histologic findings that
correlated with the MRI results. Conversely, 5 (16.1%)
had no histologic correlate of MRI findings, 4 of which

were thought to have MC disease and one thought to
have MF disease. Overall, of the 244 patients who
underwent MRI, 30 (12.3%) underwent mastectomy
because of a positive MRI; 5 patients with false
positive results and 25 with true positive results. All 5
patients with false positive MRI findings were offered
MRI guided biopsy of their additional MRI finding,
but refused biopsy and instead chose to move
forward with mastectomy.

Discussion
In our retrospective review of this prospectively
collected data set, we found that after a standardized
protocol of pre-operative MRI was initiated, patients
who underwent MRI had a higher mastectomy rate
than historical controls without MRI, but had less
need for re-excision. Routine pretreatment MRI was
not associated with delay in care, with initial surgery
occurring in approximately the same interval after
diagnosis, and margin-negative surgery actually
being accomplished more quickly in patients
receiving MRI. Importantly, over half of the patients
in the MRG choosing mastectomy did so because of
their preference, not because of the MRI findings.
Additionally, roughly 10% of patient had true positive
MRIs leading to mastectomy, while only 5 patients
(2.1%) underwent mastectomy because of false
positive findings on MRI.
A number of studies have reported increased
mastectomy rate when women undergo pre-operative
MRI, and our results reinforce this finding. While
there is clearly a correlation between MRI and
mastectomy, a direct causal relationship is not as
clear. Our study is based on retrospective analysis and
a comparison of historical controls to more recently
evaluated patients. This difference in temporal
evaluation of patients makes the observed difference
difficult to interpret as mastectomy rates across the
United States have been increasing over the last 10
http://www.jcancer.org
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years. A recent report of NSQIP data from 2005-2011
showed a relative increase in mastectomy of 2.9% per
year during that time (13). Additionally, the SEER
database showed the mastectomy rate in 2011 was
46% (14), which is roughly the same as the
mastectomy rate in the MRG. Meanwhile, our control
group mastectomy rate of 17.9% was quite low
compared to the national average at that time
(roughly 40%) (13). Furthermore, even within our
own study, there was an increase in the mastectomy
rate comparing patients from the first 2 years to later
patients. This difference may be in part due to the
MRG all being treated later in the trial, but even
within the MRG, an increase in mastectomy in the
latter portion of the trial was observed, though this
difference was not as large.
The relationship between MRI and mastectomy
is indeed complicated, as the social acceptance of
mastectomy has evolved during the same time period
in which MRI use has increased, making it difficult to
identify the causative factor. Aranaout et al. found an
increase in mastectomy associated with MRI use, but
the use of MRI increased from 3% at the beginning of
their study (2003) to 24% at the end (2012), during
roughly the same time that Lucas, et al. showed an
increase in mastectomy rates independent of any
specific imaging (2, 13). Given the complicated nature
of literature on this issue, we closely reviewed charts
of MRG patients choosing mastectomy to discern the
reasons for this choice. We found that over half of the
patients choosing mastectomy after MRI did so
because of choice, despite having negative MRIs. Only
26% of women choosing mastectomy in the MRG did
so because of MRI findings. Indeed, the increase in
MRI use over the past decade has coincided with, but
did not necessarily cause, the trend of increased
mastectomy during the same time. Ultimately, the use
MRI in our study, similar to multiple others, is
correlated with increased mastectomy, but was not
the only cause of this increase.
While a certain percent of mastectomies may be
explained by population trends, we were able to
identify a population of patients whose decision was
directly attributed to MRI findings. As noted above,
the decision to undergo initial mastectomy was
affected by MRI findings in roughly 12.3% of patients
undergoing MRI. Of these patients, pathology results
confirmed that the vast majority (83.9%) of these
findings correlated with DCIS or invasive cancer,
which likely would have likely necessitated a second
trip to the operating room for re-excision. This result
confirms the early findings reported by Barchie et al.
on the use of routine pretreatment MRI, which
showed a high specificity for MC and MF disease (11).
Additionally, we did identified a decreased
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re-excision rate in the MRG, implying that, for some,
the increased sensitivity of MRI did have clinical
benefit and, potentially, some of the mastectomies in
the MRG may have been justified. What we cannot
determine from our data set is whether these
additional findings would have affected long-term
oncologic outcomes. Randomized, prospective data
are needed to determine the ultimate meaning of this
increase in mastectomy that we, and others, have
noted. Importantly, the five patients with false
positive MRIs were offered MRI-guided biopsy, but
refused. In order to avoid similar unnecessary
mastectomies,
patients
who
do
undergo
pre-treatment MRI should be counseled regarding the
known possibility of false-positive findings and the
need for biopsy of additional findings.
The other major criticism of pretreatment MRI
has been delays in definitive surgical management. As
noted earlier, Bleicher et al. found a 22.4-day delay in
pretreatment evaluation for patients receiving MRI
(10). These delays are attributed to the process of
carrying out the test (need for approval, the time
needed to schedule and actually complete the test), as
well as the additional findings of MRI (the time
needed to work up any new findings with additional
imaging and/or biopsies). In our trial, however, we
found no increase in time to surgery for the MRG.
This finding, which is in stark contrast to most
contemporary data, is likely in part attributed to
ubiquitous and protocolized use of “in-house” MRI,
which streamlines the process. Additionally, the
ability to complete the MRI and any further work-up
within a single institution decreases delays associated
with scheduling and completing tests at multiple
facilities. While this may not be applicable to all health
systems, our data show that it is possible to obtain
pre-operative MRI without significant delay.
In addition to time to initial surgery, we
examined a potentially more clinically meaningful
end-point, time to margin-negative resection. Likely
due to a decreased re-excision rate in the MRG, we
found that pretreatment MRI actually led to a trend
towards decreased time to margin-negative resection.
Ultimately, rather than basing merit of a pre-operative
test on how quickly a patient undergoes an initial
operation, a better metric might be time to completion
of surgical treatment (to include reoperation for
positive margins). This outcome better correlates with
the start of recovery from surgery, start of adjuvant
therapies, and, importantly, return to regular life
without the stress of waiting for the result of another
pathologic assessment. We suggest that time to
margin-negative surgery, rather than time to initial
surgery, is a more meaningful end-point for the
evaluation of a pre-operative imaging modality.
http://www.jcancer.org

Journal of Cancer 2017, Vol. 8
While our results are interesting, our institution
is somewhat unique. We have a single, large medical
center where the majority of our patients receive all of
their care, to include all imaging and image-guided
biopsies. Also, almost all of our patients fall within a
single payer system, with no debate regarding
insurance coverage of diagnostic tests that are not
currently standard-of-care. Perhaps most importantly,
we have instituted a standardized protocol of
pre-operative MRI. Our results indicate that these
factors allow for the completion of pre-operative MRI
without any delay in care. While this may not
translate to every health care system, it offers a
glimpse of what is possible and indicates that if such a
system can be instituted, concern for delaying a
patient’s care should not dissuade clinicians from the
use of MRI.
There are several limitations to this study. First,
this is a retrospective review with a non-randomized
and non-contemporary control group. This introduces
a number of issues, particularly because the rate of
mastectomy has increased nationwide during the time
of our study. Additionally, our control group is rather
small, opening it to additional bias, such as the low
number of women choosing mastectomy in the CG, as
discussed above. Finally, our patient register is not set
up to maintain lengthy follow-up records and, thus,
we do not have long-term outcomes data on our
patients. One of the true tests for pre-treatment MRI
will be whether the increased sensitivity and change
in surgical approach will affect oncologic outcomes.
Specifically, will a decrease in positive margins with
pre-operative MRI lead to a decrease in the local
recurrence rate and, potentially, a decrease in
disease-specific mortality? Unfortunately, our data
does not allow us to comment on this potential
outcome.

Conclusion
In conclusion, we have performed a
retrospective review of our prospectively gathered
database of breast cancer patients at our institution.
We instituted a protocol to accomplish routine
pre-treatment MRI for all women with a diagnosis of
invasive breast cancer and compared patients who
underwent pretreatment MRI to those who did not.
Patients receiving MRI did have increased
mastectomy rates as expected from previous reports,
but had a lower re-excision rate. We found no delay to
initial surgical therapy and perhaps more
importantly, a slight decrease in time to
margin-negative surgical therapy in the MRG.
Women choosing mastectomy after MRI did so
because of personal preference (and despite negative
MRI findings) over half of the time, while MRI
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findings influenced this choice in 26% of these
women. When MRI findings did lead to mastectomy,
these findings were confirmed on histology in the vast
majority of cases. Future studies will be focused on
applying this protocol in non-invasive disease and
comparing our invasive patients to those of other
similar military hospitals, where pre-treatment MRI is
used more sparingly to assess oncologic outcomes.
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